Teva Pharmaceutical Industries Limited (NYSE:TEVA) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -2.72% to 41.79 with about 11.29 Million shares have changed hands in this session. Teva Pharmaceutical Industries Ltd., (TEVA) reported the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending an indication extension of Trisenox.
The indication extension is for use in newly diagnosed low to intermediate risk Acute Promyelocytic Leukemia in combination with retinoic acid. The firm stated, if the European Commission approves the label extension, it would mark the first time that a form of acute leukemia can be effectively treated with a regimen that is entirely chemotherapy-free. A final decision by the European Commission is predictable by the end of the year. The stock is going forward its fifty-two week low with -2.70% and lagging behind from its 52-week high price with -36.00%.
Same, the positive performance for the quarter recorded as -21.53% and for the year was -29.62%, while the YTD performance remained at -35.11%. TEVA has Average True Range for 14 days of 1.08.
Voya Infrastructure, Industrials and Materials Fund (NYSE:IDE) reported that important information concerning its distribution reported in September 2016. This press release is issued as required by the Fund’s Managed Distribution Plan and an exemptive order attained from the U.S. Securities and Exchange Commission. The Board of Trustees has agreed the implementation of the Plan to make quarterly cash distributions to ordinary shareholders, stated in terms of a fixed amount per ordinary share.
The amounts and sources of distributions reported in this notice are anticipates, are not being provided for tax reporting purposes and the distribution may later be determined to be from other sources comprising realized short-term gains, long-term gains, to the extent permitted by law, and return of capital. The actual amounts and sources for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations.